Menéndez A M, De Portela M L, Weisstaub A, Montemerlo H, Guidoni M E, Rusí F, Zeni S
Instituto Argentino de Educación e Investigación en Nutrición, Buenos Aires, Argentina.
Nutr Hosp. 2009 May-Jun;24(3):340-6.
To study the interrelationship between serum Interleukin-6 (IL-6), serum Interleukin-6 soluble Receptor (IL-6 sR), C-Reactive Protein (C-RP), plasmatic Zinc levels (PlZn) and their response in relation to Zn administered by TPN, in critical patients.
17 patients, receiving TPN as a consequence of acute pancreatitis (n = 4) or after a major abdominal surgery due to intestinal cancer (n = 7), intestinal fístula (n = 3), intestinal obstruction (n = 2) or intestinal íleus (n = 1) were studied. At the beginning (To) and at the end of the TPN administration (6-21 days) serum IL-6 and IL-6 sR were determined by ELISA; C-RP ultrasensitive (C-RP us) by inmunoturbidimetric method; Zn was determined in TPN and in plasma by Atomic Absorption Spectrometry. Characteristics of the patients were (mean +/- SD and ranges): age: 60.6 +/- 11.7 (37-77) years; BMI (kg/m(2)): 26.0 +/- 3.4 (19.9-34.0).
The results (mean +/- standard deviation and ranges) were: Zn provided by TPN (mg/d): 6.1 +/- 2.0 (range 2.8 to 10.8). Biochemical levels were, at To and Tf, respectively: (mean+/-SD and ranges) were at To y Tf, respectively: Zn Pl (microg/dl): 104 +/- 46 (35-177); 120 +/- 55 (52-229); IL-6 (pg/mL) 93 +/- 74 (10-262); 117 +/- 180 (7-761); IL6sR (pg/mL): 1,012 +/- 322 (589-1855); 1,269 +/- 451 (631-2195); C-RP us (mg/L): 71 +/- 63 (2-196); 65 +/- 43 (0-137). There was no correlation between variations of IL6, IL6sR, C-RP, PlZn levels and the daily amount of Zn administered in the TPN mixtures. Two patients presented a bad evolution; they received 4.2 and 5.2 md/d of Zn and showed an increase of IL6 levels, maintained high levels of IL6sR but C-RP levels decreased.
the range of 2.8 to 10.8 mg/d of Zn administered in TPN mixtures did not exacerbate the inflammatory response.
研究危重症患者血清白细胞介素-6(IL-6)、血清白细胞介素-6可溶性受体(IL-6 sR)、C反应蛋白(C-RP)、血浆锌水平(PlZn)之间的相互关系,以及它们对全胃肠外营养(TPN)中锌补充的反应。
研究17例因急性胰腺炎(n = 4)或因肠癌(n = 7)、肠瘘(n = 3)、肠梗阻(n = 2)或肠麻痹(n = 1)接受大腹部手术后接受TPN的患者。在TPN开始时(T0)和结束时(6 - 21天),采用酶联免疫吸附测定法(ELISA)测定血清IL-6和IL-6 sR;采用免疫比浊法测定超敏C反应蛋白(C-RP us);采用原子吸收光谱法测定TPN和血浆中的锌。患者特征为(均值±标准差及范围):年龄:60.6±11.7(37 - 77)岁;体重指数(BMI,kg/m²):26.0±3.4(19.9 - 34.0)。
结果(均值±标准差及范围)为:TPN提供的锌(mg/d):6.1±2.0(范围2.8至10.8)。生化指标在T0和Tf时分别为:(均值±标准差及范围),锌血浆(μg/dl):104±46(35 - 177);120±55(52 - 229);IL-6(pg/mL)93±74(10 - 262);117±180(7 - 761);IL6sR(pg/mL):1,012±322(589 - 1855);1,269±451(631 - 2195);C-RP us(mg/L):71±63(2 - 196);65±43(0 - 137)。IL6、IL6sR、C-RP、PlZn水平的变化与TPN混合液中每日锌给药量之间无相关性。两名患者病情进展不佳;他们接受了4.2和5.2 mg/d的锌,IL6水平升高,IL6sR水平维持在高位,但C-RP水平下降。
TPN混合液中2.8至10.8 mg/d的锌剂量范围不会加剧炎症反应。